SG11201810793XA - Pharmaceutical combinations - Google Patents
Pharmaceutical combinationsInfo
- Publication number
- SG11201810793XA SG11201810793XA SG11201810793XA SG11201810793XA SG11201810793XA SG 11201810793X A SG11201810793X A SG 11201810793XA SG 11201810793X A SG11201810793X A SG 11201810793XA SG 11201810793X A SG11201810793X A SG 11201810793XA SG 11201810793X A SG11201810793X A SG 11201810793XA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- pharmaceutical combinations
- pharmaceutically acceptable
- pct
- acceptable salt
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
TumorVo lume ( mm ) 800- 400- W O 20 17 / 2105 38 Al (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 07 December 2017 (07.12.2017) WIPO I PCT ill~~~~~~~~ 011101tIIl tun Hol Holum ono iflo oimIE (10) International Publication Number WO 2017/210538 Al (51) International Patent Classification: A61K 31/4184 (2006.01) A61K 31/506 (2006.01) (21) International Application Number: PCT/US2017/035653 (22) International Filing Date: 02 June 2017 (02.06.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/345,389 03 June 2016 (03.06.2016) US (72) Inventors; and (71) Applicants: CAPONIGRO, Giordano [US/US]; 3200 Walnut St., Boulder, CO 80301 (US). CAO, Zhu, Alexan- der [US/US]; 3200 Walnut St., Boulder, CO 80301 (US). (74) Agent: KENDALL, John, T. et al.; Fish & Richardson P.C., P.O. Box 1022, Minneapolis, MN 55440-1022 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (54) Title: PHARMACEUTICAL COMBINATIONS 1200 - Vehicle/IgG control -A- Cetuximab 20mg/kg 2qw ip fi LGX818 20mg/kg qd po u LGX818 + Cetuximab Last treatment 0 22 29 36 Days Post Implantation 43 FIG. IA (57) : Provided herein are pharmaceutical combinations comprising (a) a B-Raf inhibitor, or a pharmaceutically acceptable salt thereof, (b) at least one mitogen activated protein kinase (MEK) inhibitor, or a pharmaceutically acceptable salt thereof, and (c) an epidermal growth factor receptor (EGFR) inhibitor or a pharmaceutically acceptable salt thereof; and optionally at least one pharma- ceutically acceptable carrier; methods for preparing the pharmaceutical combinations, and the uses of the pharmaceutical combinations in the treatment of proliferative diseases, such as cancer. [Continued on next page] WO 2017/210538 Al MIDEDIMOMMIDIRMEMIHOIDINIM011110111111111111 Published: — with international search report (Art. 21(3))
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662345389P | 2016-06-03 | 2016-06-03 | |
| PCT/US2017/035653 WO2017210538A1 (en) | 2016-06-03 | 2017-06-02 | Pharmaceutical combinations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201810793XA true SG11201810793XA (en) | 2018-12-28 |
Family
ID=60477982
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201810793XA SG11201810793XA (en) | 2016-06-03 | 2017-06-02 | Pharmaceutical combinations |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US10485788B2 (en) |
| EP (1) | EP3463345B1 (en) |
| JP (2) | JP6805336B2 (en) |
| KR (1) | KR102439911B1 (en) |
| CN (1) | CN109890386B (en) |
| AU (1) | AU2017275650B2 (en) |
| BR (1) | BR112018074941A2 (en) |
| CA (1) | CA3026361A1 (en) |
| CL (1) | CL2018003421A1 (en) |
| CO (1) | CO2019000010A2 (en) |
| CR (1) | CR20190002A (en) |
| DK (1) | DK3463345T3 (en) |
| FI (1) | FI3463345T3 (en) |
| HU (1) | HUE060653T2 (en) |
| IL (1) | IL263431A (en) |
| MA (1) | MA45187A (en) |
| MX (1) | MX2018014973A (en) |
| PH (1) | PH12018502549A1 (en) |
| PL (1) | PL3463345T3 (en) |
| PT (1) | PT3463345T (en) |
| RU (1) | RU2759669C2 (en) |
| SG (1) | SG11201810793XA (en) |
| SI (1) | SI3463345T1 (en) |
| UA (1) | UA125436C2 (en) |
| WO (1) | WO2017210538A1 (en) |
| ZA (1) | ZA201900019B (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201810793XA (en) | 2016-06-03 | 2018-12-28 | Giordano Caponigro | Pharmaceutical combinations |
| CN109715163B (en) * | 2016-09-19 | 2022-11-22 | 诺华股份有限公司 | Therapeutic combination comprising a RAF inhibitor and an ERK inhibitor |
| CN114746950A (en) * | 2019-10-11 | 2022-07-12 | 豪夫迈·罗氏有限公司 | Medication dose determination apparatus and method |
| EP4103286A4 (en) * | 2020-02-10 | 2024-03-20 | Cedars-Sinai Medical Center | Method of treating pancreatic cancer |
| JP7288220B2 (en) | 2021-03-29 | 2023-06-07 | ダイキン工業株式会社 | Motors, blowers, and refrigerators |
| WO2023230554A1 (en) | 2022-05-25 | 2023-11-30 | Pfizer Inc. | Combination of a braf inhibitor, an egfr inhibitor, and a pd-1 antagonist for the treatment of braf v600e-mutant, msi-h/dmmr colorectal cancer |
| WO2024126660A1 (en) * | 2022-12-15 | 2024-06-20 | F. Hoffmann-La Roche Ag | Combination therapy for cancer treatment |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4128089A (en) | 1988-09-15 | 1990-03-22 | Rorer International (Overseas) Inc. | Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same |
| AU6267896A (en) | 1995-06-07 | 1996-12-30 | Imclone Systems Incorporated | Antibody and antibody fragments for inhibiting the growth oftumors |
| ES2549159T3 (en) | 2002-03-13 | 2015-10-23 | Array Biopharma, Inc. | N3-alkylated benzimidazole derivatives as MEK inhibitors |
| US7235537B2 (en) * | 2002-03-13 | 2007-06-26 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as MEK inhibitors |
| WO2008120004A1 (en) | 2007-04-02 | 2008-10-09 | Astrazeneca Ab | Combination of a mek- inhibitor and a b-raf inhibitor for the treatment of cancer |
| CN102105459B (en) | 2008-07-24 | 2014-09-10 | 内尔维阿诺医学科学有限公司 | 3,4-diarylpyrazoles as protein kinase inhibitors |
| JP5527878B2 (en) * | 2009-07-30 | 2014-06-25 | トムソン ライセンシング | Display device and audio output device |
| JO3002B1 (en) | 2009-08-28 | 2016-09-05 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| CA2838736A1 (en) * | 2011-06-07 | 2012-12-13 | Caris Mpi, Inc. | Molecular profiling for cancer |
| CA2855243C (en) * | 2011-11-11 | 2020-04-14 | Novartis Ag | Method of treating a proliferative disease |
| MY172729A (en) | 2011-11-23 | 2019-12-11 | Array Biopharma Inc | Pharmaceutical formulations |
| AR091876A1 (en) * | 2012-07-26 | 2015-03-04 | Novartis Ag | PHARMACEUTICAL COMBINATIONS FOR THE TREATMENT OF PROLIFERATIVE DISEASES |
| NZ703940A (en) * | 2012-08-07 | 2018-04-27 | Novartis Ag | Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor |
| FI3702351T3 (en) | 2012-10-19 | 2024-01-24 | Array Biopharma Inc | Formulation comprising a mek inhibitor |
| AU2013334599B2 (en) * | 2012-10-25 | 2016-03-10 | Novartis Ag | Combination |
| CN105209073A (en) | 2013-03-21 | 2015-12-30 | 诺华股份有限公司 | Combination therapy comprising a B-Raf inhibitor and a second inhibitor |
| US9447013B2 (en) | 2013-07-18 | 2016-09-20 | Daicel Corporation | Method for producing oxide |
| US20150087279A1 (en) * | 2013-09-20 | 2015-03-26 | Better Mousetrap, LLC | Mobile accident processing system and method |
| AU2014362995A1 (en) * | 2013-12-12 | 2016-05-26 | Novartis Ag | Combinations of trametinib, panitumumab and dabrafenib for the treatment of cancer |
| CN105566225A (en) * | 2015-02-16 | 2016-05-11 | 苏州晶云药物科技有限公司 | Crystal forms of orally-taken mitogen-activated protein kinase inhibitor and preparation method of crystal forms |
| US10323035B2 (en) * | 2015-04-01 | 2019-06-18 | Crystal Pharmatech Co., Ltd. | Co-crystal of a CDK inhibitor and an MEK inhibitor and process of preparation thereof |
| WO2017019279A1 (en) | 2015-07-27 | 2017-02-02 | Southern Research Institute | Methods and compositions to treat cancers involving egfr |
| SG11201810793XA (en) | 2016-06-03 | 2018-12-28 | Giordano Caponigro | Pharmaceutical combinations |
-
2017
- 2017-06-02 SG SG11201810793XA patent/SG11201810793XA/en unknown
- 2017-06-02 HU HUE17807555A patent/HUE060653T2/en unknown
- 2017-06-02 CR CR20190002A patent/CR20190002A/en unknown
- 2017-06-02 JP JP2019515782A patent/JP6805336B2/en active Active
- 2017-06-02 KR KR1020187037798A patent/KR102439911B1/en active IP Right Grant
- 2017-06-02 MX MX2018014973A patent/MX2018014973A/en unknown
- 2017-06-02 DK DK17807555.2T patent/DK3463345T3/en active
- 2017-06-02 PT PT178075552T patent/PT3463345T/en unknown
- 2017-06-02 AU AU2017275650A patent/AU2017275650B2/en active Active
- 2017-06-02 FI FIEP17807555.2T patent/FI3463345T3/en active
- 2017-06-02 MA MA045187A patent/MA45187A/en unknown
- 2017-06-02 SI SI201731293T patent/SI3463345T1/en unknown
- 2017-06-02 PL PL17807555.2T patent/PL3463345T3/en unknown
- 2017-06-02 UA UAA201813074A patent/UA125436C2/en unknown
- 2017-06-02 CA CA3026361A patent/CA3026361A1/en active Pending
- 2017-06-02 WO PCT/US2017/035653 patent/WO2017210538A1/en unknown
- 2017-06-02 CN CN201780048857.2A patent/CN109890386B/en active Active
- 2017-06-02 EP EP17807555.2A patent/EP3463345B1/en not_active Revoked
- 2017-06-02 BR BR112018074941-9A patent/BR112018074941A2/en active Search and Examination
- 2017-06-02 RU RU2018146812A patent/RU2759669C2/en active
-
2018
- 2018-11-30 CL CL2018003421A patent/CL2018003421A1/en unknown
- 2018-12-03 PH PH12018502549A patent/PH12018502549A1/en unknown
- 2018-12-03 IL IL263431A patent/IL263431A/en unknown
- 2018-12-03 US US16/208,172 patent/US10485788B2/en active Active
-
2019
- 2019-01-02 ZA ZA2019/00019A patent/ZA201900019B/en unknown
- 2019-01-02 CO CONC2019/0000010A patent/CO2019000010A2/en unknown
- 2019-09-24 US US16/580,505 patent/US11376239B2/en active Active
-
2020
- 2020-12-03 JP JP2020201152A patent/JP2021054832A/en active Pending
-
2022
- 2022-05-16 US US17/745,136 patent/US20230044943A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201810793XA (en) | Pharmaceutical combinations | |
| SG11201908532UA (en) | Macrocyclic compounds as ros1 kinase inhibitors | |
| SG11201808125RA (en) | Methods for solid tumor treatment | |
| SG11201901126UA (en) | Combination therapy for cancer | |
| SG11201803728YA (en) | Topical pharmaceutical formulations for treating inflammatory-related conditions | |
| SG11201804373VA (en) | Compositions and methods for immunooncology | |
| SG11201907846VA (en) | Therapeutic rna | |
| SG11201910101SA (en) | Alphavirus neoantigen vectors | |
| SG11201807965YA (en) | Combinations of lsd1 inhibitors for use in the treatment of solid tumors | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201906431UA (en) | Method for the treatment of thromboembolism | |
| SG11201903155XA (en) | Pharmaceutical compounds | |
| SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
| SG11201808676RA (en) | Methods of treating pediatric cancers | |
| SG11201407486PA (en) | Compositions and methods for modulating utrn expression | |
| SG11201804263PA (en) | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor | |
| SG11201909155VA (en) | Ask1 inhibitor compounds and uses thereof | |
| SG11201908326YA (en) | Methods of treating neurodegenerative diseases | |
| SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
| SG11201901228QA (en) | Chromatography method for quantifying a non-ionic surfactant in a composition comprising the non-ionic surfactant and a polypeptide | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
| SG11201806544XA (en) | Compounds and methods of treating rna-mediated diseases | |
| SG11201908603PA (en) | Macrocyclic compound and uses thereof | |
| SG11201805755SA (en) | Methods of administering hepcidin |